3-heptyldecanoic acid | 736981-73-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-heptyldecanoic acid
• 英文别名: 3-Heptyl-decansaeure
• CAS: 736981-73-0
• 化学式: C₁₇H₃₄O₂
• 分子量: 270.456
• InChiKey: NLMPTHDIKIOXAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  19
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-heptyldecanoic acid 在 戊醇 、 硫酸 、 sodium 作用下， 生成 3-heptyl-decan-1-ol
  参考文献：
  名称：

  Asano; Yamakawa, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1950, vol. 70, p. 474

  摘要：

  DOI：
• 作为产物：
  描述：

  1-iodopentadecane 在 氢氧化钾 、 乙醇 作用下， 生成 3-heptyldecanoic acid
  参考文献：
  名称：

  Asano; Yamakawa, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1950, vol. 70, p. 474

  摘要：

  DOI：

文献信息

• LIPID COMPOSITION
  申请人：FUJIFILM Corporation

  公开号：US20220096381A1

  公开（公告）日：2022-03-31

  An object of the present invention is to provide a lipid composition making it possible to achieve excellent delivery of nucleic acids. According to the present invention, there is provided a lipid composition containing a lipid represented by Formula (1) or a salt thereof, a nonionic lipid, a lipid having a nonionic hydrophilic polymer structure, and a nucleic acid, in which the lipid composition contains or does not contain a zwitterionic lipid, and in a case where (A) represents a molar ratio in percentage of the lipid represented by Formula (1) or a salt thereof to total lipids constituting the lipid composition and (B) represents a molar ratio in percentage of the zwitterionic lipid to total lipids constituting the lipid composition, (A) and (B) satisfy 40<(A)−(B)≤90. In the formula, X represents —NR 1 — or —O—, R 1 represents a hydrogen atom, a hydrocarbon group, or the like, R 2 and R 3 each independently represent a hydrogen atom, a hydrocarbon group, or the like, R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 each independently represent a hydrogen atom or an alkyl group, groups in any one or more pairs among R 4 and R 5 , R 10 and R 5 , R 5 and R 12 , R 4 and R 6 , R 5 and R 6 , R 6 and R 7 , R 6 and R 10 , R 12 and R 7 , and R 7 and R 8 may be linked to each other to form a 4- to 7-membered ring which may contain an O atom, a, b, c, and d are each independently represent an integer of 0 to 3, a+b is 1 or more, and c+d is 1 or more.

  本发明的目的是提供一种脂质组合物，使得核酸的传递能够实现优异。根据本发明，提供一种脂质组合物，其中包含式（1）或其盐所代表的脂质、非离子脂质、具有非离子亲水性聚合物结构的脂质和核酸，所述脂质组合物包含或不包含一个带电离子脂质，且当（A）代表式组成脂质组合物中式（1）或其盐所代表的脂质的摩尔比例百分比，（B）代表式组成脂质组合物中带电离子脂质的摩尔比例百分比时，（A）和（B）满足40 < (A) - (B) ≤ 90。在式中，X代表—NR1—或—O—，R1代表氢原子、烃基或类似物，R2和R3各自独立地代表氢原子、烃基或类似物，R4、R5、R6、R7、R8、R9、R10、R11和R12各自独立地代表氢原子或烷基，R4和R5、R10和R5、R5和R12、R4和R6、R5和R6、R6和R7、R6和R10、R12和R7以及R7和R8中的任意一个或多个成对的基团可以连接在一起形成一个含氧原子的4-7环，a、b、c和d各自独立地代表0到3的整数，a+b≥1，c+d≥1。
• Chemical Hybridization of Vizantin and Lipid A to Generate a Novel LPS Antagonist
  作者：Hirofumi Yamamoto、Masataka Oda、Marina Kanno、Shota Tamashiro、Ikuko Tamura、Toshihiko Yoneda、Naoto Yamasaki、Hisanori Domon、Mayo Nakano、Hironobu Takahashi、Yutaka Terao、Yusuke Kasai、Hiroshi Imagawa

  DOI：10.1248/cpb.c15-00828

  日期：——

  Lipopolysaccharide (LPS) antagonists have attracted considerable interest as promising candidates for the treatment of severe sepsis triggered by Gram-negative bacteria. In this article, we describe the development of a novel LPS antagonist based on chemical hybridization of vizantin and the hydrophobic molecular unit of LPS (lipid A). Vizantin, 6,6′-bis-O-(3-nonyldodecanoyl)-α,α′-trehalose, was designed as an immunostimulator from a structure–activity relationship (SAR) study with trehalose 6,6′-dicorynomycolate (TDCM). Our recent study indicated that vizantin displays adjuvant activity by specifically binding to the Toll-like receptor 4 (TLR4)/MD2 protein complex. Because lipid A unit (or LPS) is also known to trigger an inflammatory response via the same TLR4/MD2 complex as vizantin, we designed a hybrid compound of vizantin and lipid A with the aim of developing a novel biofunctional glycolipid. Focusing on the antagonism to Escherichia coli LPS in an in vitro model with human macrophages (THP-1 cells), we identified a potent LPS antagonist among the synthesized hybrid compounds. The novel LPS antagonist effectively inhibited LPS-induced release of tumor necrosis factor-alpha (TNF-α) in a dose-dependent manner with an IC50 value of 3.8 nM, making it a candidate for the treatment drug of Gram-negative sepsis and/or septic shock.

  脂多糖（LPS）拮抗剂作为治疗由革兰氏阴性细菌引发的严重败血症的候选药物，引起了人们的极大兴趣。在这篇文章中，我们介绍了一种新型 LPS 拮抗剂的开发情况，它基于 vizantin 与 LPS 的疏水分子单元（脂质 A）的化学杂交。Vizantin（6,6′-双-O-(3-壬基十二碳酰基)-α,α′-曲哈洛糖）是通过与 6,6′-二硼酸曲哈洛糖（TDCM）的结构-活性关系（SAR）研究而设计的一种免疫刺激剂。我们最近的研究表明，vizantin 通过与 Toll 样受体 4（TLR4）/MD2 蛋白复合物特异性结合而显示出佐剂活性。众所周知，脂质 A 单位（或 LPS）也能通过与 vizantin 相同的 TLR4/MD2 复合物触发炎症反应，因此我们设计了一种 vizantin 和脂质 A 的混合化合物，旨在开发一种新型生物功能糖脂。在以人巨噬细胞（THP-1 细胞）为对象的体外模型中，我们重点研究了大肠杆菌 LPS 的拮抗作用，并在合成的混合化合物中发现了一种强效的 LPS 拮抗剂。这种新型 LPS 拮抗剂能以剂量依赖的方式有效抑制 LPS 诱导的肿瘤坏死因子-α（TNF-α）的释放，其 IC50 值为 3.8 nM，因此可作为革兰氏阴性败血症和/或脓毒性休克的候选治疗药物。
• COMPOUND, SALT THEREOF AND LIPID PARTICLES
  申请人：FUJIFILM Corporation

  公开号：EP3805198A1

  公开（公告）日：2021-04-14

  An object of the present invention is to provide a compound or a salt thereof constituting lipid particles that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids, and to provide lipid particles that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids. According to an aspect of the present invention, a compound represented by Formula (1) or a salt thereof is provided. In the formula, X represents -NR1- or -O-, R1 represents a hydrogen atom, a hydrocarbon group, or the like, R2 and R3 each independently represent a hydrogen atom, a hydrocarbon group, or the like, R4, R5, R6, R7, R8, R9, R10, R11, and R12 each independently represent a hydrogen atom or an alkyl group, groups in any one or more pairs among R4 and R5, R10 and R5, R5 and R12, R4 and R6, R5 and R6, R6 and R7, R6 and R10, R12 and R7, and R7 and R8 may be linked to each other to form a 4- to 7-membered ring which may contain an O atom, a, b, c, and d are each independently represent an integer of 0 to 3, a + b is equal to or greater than 1, and c + d is equal to or greater than 1.

  本发明的目的是提供一种化合物或其盐类构成的脂质微粒，该脂质微粒可实现较高的核酸包封率和核酸的良好递送，并提供可实现较高的核酸包封率和核酸的良好递送的脂质微粒。根据本发明的一个方面，提供了一种由式（1）代表的化合物或其盐。 式中，X代表-NR1-或-O-，R1代表氢原子、烃基或类似物，R2和R3各自独立地代表氢原子、烃基或类似物，R4、R5、R6、R7、R8、R9、R10、R11和R12各自独立地代表氢原子或烷基、R4和R5之间任意一对或多对的基团、R10 和 R5、R5 和 R12、R4 和 R6、R5 和 R6、R6 和 R7、R6 和 R10、R12 和 R7 以及 R7 和 R8 中的任意一对或多对基团可彼此相连，形成可包含 O 原子的 4 至 7 元环，a、b、c 和 d 各自独立地代表 0 至 3 的整数，a + b 等于或大于 1，c + d 等于或大于 1。
• 阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统
  申请人：深圳市新合生物医疗科技有限公司

  公开号：CN116283624A

  公开（公告）日：2023-06-23

  本发明是关于一种阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统；解决亟需开发递送效率高、免疫激活特性优异的阳离子质脂的问题。其中，阳离子脂质化合物的结构如下式(I)所示： 其中，在式(I)：X为O或N；n为2‑4；m为2‑4；a为0或1；R
• HAIR COSMETIC COMPOSITION
  申请人：Kao Corporation

  公开号：EP0651632A1

  公开（公告）日：1995-05-10